ASN
GALT icon

Advisory Services Network’s Galectin Therapeutics GALT Stock Holding History

Advisory Services Network’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-500
Closed -$3K – 2581
2018
Q3 		$3K Buy
+500
New +$2.75K ﹤0.01% 2217

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advisory Services Network's GALT Position: Q4 2018 in Review

Advisory Services Network sold out of Galectin Therapeutics (GALT) in Q4 2018, closing a stake of 500 shares — an estimated $3K sold.

Advisory Services Network first reported a position in GALT in Q3 2018 and held it in 1 quarter. The position peaked at $3K in Q3 2018. 61 funds tracked by Wall St. Rank hold GALT as of Q4 2018.

  • Advisory Services Network reported no remaining Galectin Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Advisory Services Network sold 500 Galectin Therapeutics shares in Q4 2018, an estimated $3K.
  • Advisory Services Network first reported a position in Galectin Therapeutics in Q3 2018 and held it in 1 quarter.
  • Advisory Services Network's Galectin Therapeutics position peaked at $3K in Q3 2018.
  • 61 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2018.

Based on Advisory Services Network's 13F filing for Q4 2018, filed 15 Feb 2019.